作为核苷类原料药细分领域的标杆企业，拓新药业此次战略投资瞄准的是全球抗衰市场的新风口。 仅三生物依托合成生物技术，不仅实现了 99.99%超高纯度麦角硫因的规模化量产，更凭借其在 多领域人体临床研究上的突破性成果，一举奠定其作为全球麦角硫因行业核心巨头与标准引领者的 地位。 01 战略转型：拓新药业的跨界投资逻辑 拓新药业集团股份有限公司成立于 2001年，是以原料药及医药中间体为主，集研发、生产及销售 为一体的医药公司，凭借在核苷类似物领域二十余年的深耕细作，现已发展成为该细分领域的标杆 企业。 2024年，公司"前瞻性布局营养强化剂、食品添加剂及保健食品领域，成功储备麦角硫 因、谷胱甘肽、辅酶Q10等热门功能原料的核心制备技术"。 作为在核苷（酸）类原料药领域深耕 24年的企业，拓新药业拥有雄厚的技术积累。公司先后获得 国家科学技术进步二等奖、河南省科学技术进步一等奖等重大科技奖项，建成"国家博士后科研工 作站"、"河南省博士后研发基地"，技术实力毋庸置疑。 资本事件 | 仅三生物 【SynBioCon】 获悉， 7月16日，深圳证券交易所创业板上市企业 拓新药业集团股份有限公司 （股票代码：301089 ...

Group 1 - The core point of the article is that Tuoxin Pharmaceutical has invested 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, which will enhance its capabilities in the health sector [1][3] - The investment agreement stipulates that the funds will be used solely for the development and operation of Jinsan Biotechnology's main business [1] - Tuoxin Pharmaceutical is actively expanding into the health sector, developing nutritional supplements, food additives, and health foods, with successful mass production of certain functional foods [1][2] Group 2 - In 2024, Tuoxin Pharmaceutical has focused on "technological innovation, dynamic product structure optimization, and deep integration of the industrial chain" to address core business fluctuations and cultivate new growth points [2] - The company has established multiple technology platforms, including chemical synthesis and synthetic biology, and has improved the conversion of R&D results [2] - Tuoxin Pharmaceutical plans to accelerate the R&D and registration of health products over the next three years, aiming to create a complete commercialization chain [2] Group 3 - Jinsan Biotechnology specializes in the research, production, and application of ergotioneine, with breakthroughs in fermentation and purification technologies [3] - The main products of Jinsan Biotechnology include skincare products, oral capsules, and eye wash solutions [3] - Tuoxin Pharmaceutical's investment in Jinsan Biotechnology is a strategic move to extend its production, sales, and R&D chain, enhancing market competitiveness and profitability [3]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

第 674 期 2025-07-17 焦点事件 支持上市公司并购重组，河南出台新政 河南省人民政府办公厅近日印发《河南省支持上市公司并购重组若干政策措施》，其中列举了7项举措，提出 鼓励上市公司通过并购重组转型升级、开辟第二增长曲线，引导更多资源向人工智能、低空经济、生物医 药、新材料、高端装备等新质生产力方向集聚。 六大行均已布局设立AIC 7月16日，邮储银行公告，拟出资100亿元发起设立中邮金融资产投资有限公司（暂定名）。至此，六大国有 行均布局金融资产投资有限公司。 中邮投资将作为邮储银行全资一级子公司管理，具体业务范围以有关监管机构批复为准。中邮投资将严格遵 循各项法律法规及监管规定，建立完善的公司治理结构，在做好风险管理基础上开展各项业务。 黄仁勋在演讲中，提及了腾讯、网易、米哈游、游戏科学、字节跳动、DeepSeek、阿里巴巴、美团、 MiniMax、百度、小米等11家中国公司。 黄仁勋表示，中国的供应链是奇迹。他预测，十年内，工厂将由软件和人工智能驱动，AI将指挥机器人团队 与人协作，智能产品的制造也将由AI驱动。"这将为中国的供应链生态创造新的机遇。"黄仁勋说道。 宏观要闻 国常会：研究做强 ...

Group 1 - The rumor of Federal Reserve Chairman Powell being fired by Trump caused significant market fluctuations, with a drop in U.S. stocks and a rise in gold and Bitcoin prices [1][3] - After Trump denied the rumors, U.S. stocks rebounded, with the S&P 500 rising by 0.32%, the Dow Jones by 0.53%, and the Nasdaq by 0.26% [1] - The 2-year U.S. Treasury yield fell by over 7 basis points during the rumor but narrowed its decline after the denial [3] Group 2 - Tesla's stock increased by 3.5% as the Model Y L is set to be delivered this fall [2] - Chip stocks experienced mixed results, with AMD rising by 3% while ASML fell by over 8% [2] - The Nasdaq Golden Dragon China Index fell by 1.41%, with notable movements in Chinese concept stocks [2] Group 3 - The U.S. House Financial Services Committee Chairman stated that there are enough votes to push forward a stablecoin bill [5] - The CEO of a major U.S. bank indicated plans to collaborate with some stablecoin projects [6] Group 4 - Major developments in China's economic policies include initiatives to boost consumption and regulate the electric vehicle industry [9][10] - The Henan provincial government has introduced policies to support mergers and acquisitions for listed companies [10] Group 5 - The tungsten market continues to see price increases, with black tungsten concentrate prices rising by 25% since the beginning of the year [21] - The Ministry of Natural Resources has reduced the tungsten mining quota for 2024 and 2023, indicating tighter supply conditions [21] Group 6 - MiniMax is nearing completion of a new financing round of approximately $300 million, with a post-financing valuation exceeding $4 billion [19] - The company is reportedly seeking an A-share listing, reflecting its commercial potential in the AI sector [19] Group 7 - The Beijing Economic Development Zone has launched a special fund to support 6G technology development, with a maximum funding of 30 million yuan for qualifying enterprises [20] - The initiative aims to establish a leading 6G innovation development area by 2030 [20]

Group 1 - Meidi Kai plans to acquire 100% equity of Haisholi and INNOWAVE VIETNAM for a total of 2 billion KRW, entering Samsung's supply chain and filling gaps in its ultra-thin optical film business [3] - Tuo Xin Pharmaceutical will invest 10 million CNY in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake, as Jinsan has successfully produced high-purity ergothioneine [4] - Zhejiang Energy Power reported a 4.48% increase in power generation to 78.848 billion kWh in the first half of the year, driven by rising electricity demand in Zhejiang province [5] Group 2 - Anker Innovation is researching overseas share issuance to enhance its global strategy and brand image, with no specific plan confirmed yet [6] - *ST Chuangxing announced a change in actual controller to Wang Xiangrong after a judicial auction of shares [7] - Hosheng Silicon Industry's controlling shareholder plans to transfer 5.08% of its shares for 2.634 billion CNY [8] Group 3 - Wuchan Zhongda's subsidiary plans to acquire 100% equity of South Taihu Technology for 1.457 billion CNY, aiming to strengthen its position in the cogeneration sector [9] - Postal Savings Bank intends to invest 10 billion CNY to establish a financial asset investment company, supporting technological innovation and private enterprises [10] - *ST Huawang plans to purchase 55.5% equity of Niwei Power for a total of approximately 6.01 billion CNY, focusing on the development of high-pressure fuel tank systems for hybrid vehicles [11] Group 4 - Tiande Yu expects a 50.89% increase in net profit to 152 million CNY in the first half of 2025, driven by growth in display driver chips [14] - Pinming Technology anticipates a net profit increase of 231.79% to 340 million CNY in the first half of 2025, attributed to growth in construction information software [15] - *ST Jinglun forecasts a loss of 19 to 22 million CNY in the first half of 2025, despite a 23.5% revenue increase [16] Group 5 - Jindi Co. signed an industrial project investment contract with the government for no less than 1.5 billion CNY to expand its market in Southwest China [17] - Baiyun Electric is expected to win a procurement project from the State Grid worth 164 million CNY [18] Group 6 - Fulei New Materials plans to reduce its stake by up to 1.33% through trading [19] - Yaxin Security's shareholders plan to collectively reduce their stake by up to 3% [20] - Zhongchong Co.'s controlling shareholder plans to reduce its stake by up to 1.5% [21] Group 7 - Huayuan Holdings intends to repurchase shares worth 20 to 40 million CNY for employee stock ownership plans [24] - Taiji Group plans to repurchase shares worth 80 to 120 million CNY, all for cancellation [25] Group 8 - Fengshen Co. plans to raise up to 1.1 billion CNY through a private placement for a tire expansion project [26] - Shangwei Co. plans to raise up to 1.144 billion CNY through a private placement to enhance its capabilities [27] - Shanggao Environmental plans to raise up to 718 million CNY through a private placement for working capital and debt repayment [28]

智通财经7月16日晚间新闻精选 4、黄仁勋表示，AI的下一波浪潮将是机器人系统，在未来十年中，工厂将由软件和AI驱动，协调人机 协作的机器人团队，生产由AI所主导的智能产品。 5、特斯拉六座版MODEL Y L登上工信部新车目录。知情人士表示，新车型计划最早第三季度上市，预 估售价将为40万元左右。 6、邮储银行：拟出资100亿元发起设立中邮金融资产投资有限公司。合盛硅业：控股股东拟转让公司 5.08%股份给肖秀艮 转让总价为26.34亿元。新易盛：预计下半年起1.6T产品将逐渐起量。拓新药业：拟 对仅三生物增资1000万元 仅三生物实现了高纯度麦角硫因的制备。 1、李强主持召开国务院常务会议，研究做强国内大循环重点政策举措落实工作；听取规范新能源汽车 产业竞争秩序情况的汇报。 2、何立峰出席第三届中国国际供应链促进博览会开幕式指出，中国将做全球产业链供应链互利共赢的 推动者。 3、国家能源局发布消息，7月16日全国电力负荷再创历史新高，首次突破15亿千瓦，较去年最大负荷增 加0.55亿千瓦。 ...

Company Focus - Postal Savings Bank plans to invest 10 billion yuan to establish China Post Financial Asset Investment Co., Ltd [2] - Anker Innovation is currently researching and evaluating equity financing in the Hong Kong capital market [2] - Hoshine Silicon Industry's controlling shareholder intends to transfer 5.08% of the company's shares to Xiao Xiukun for a total price of 2.634 billion yuan [2] - Shantui Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] Investment & Contracts - Jindi Co., Ltd. signed an industrial project investment contract with the Bishan District government for no less than 1.5 billion yuan [2] - Tuoxin Pharmaceutical intends to increase capital by 10 million yuan in Jingsan Biological, which has achieved the preparation of high-purity ergotamine [2] Equity Changes - Wuchan Huaneng plans to acquire 100% equity of Nantah Lake Technology for 1.457 billion yuan [3] - A shareholder of Aisecurity plans to reduce their holdings by no more than 3% of the company's shares [2] Performance & Earnings - Tiande Yu expects a net profit of 152 million yuan for the first half of the year, a year-on-year increase of 50.89% [4] - Pinming Technology anticipates a year-on-year net profit increase of 232%-303% for the first half of 2025 [4] Contracts & Project Wins - Pinggao Electric won a project from the State Grid with a total amount of approximately 1.45 billion yuan [4] Financing & Capital Increase - Shangwei Co., Ltd. plans to issue shares to its controlling shareholder Fuhua Chemical to raise no more than 1.144 billion yuan [2] Stock Price Movements - Zhongchen Technology's revenue from humanoid robot-related products accounts for no more than 1% of total revenue [2]

Group 1 - Postal Savings Bank plans to invest 10 billion yuan to establish China Post Financial Asset Investment Co., with a registered capital of 10 billion yuan, aiming to enhance comprehensive service capabilities and support technological innovation and private enterprises [1] - Tuo Xin Pharmaceutical intends to increase capital by 10 million yuan in Jiangsu Jin San Biotechnology Co., acquiring a 1.75% stake, with Jin San successfully producing high-purity ergothioneine for various products [2] - Anker Innovations is researching overseas share issuance to expand its global strategy and enhance brand influence, with no specific plan confirmed yet [3] Group 2 - Hoshine Silicon Industry's controlling shareholder plans to transfer 5.08% of shares to Xiao Xiugan for a total price of 2.634 billion yuan, with no change in control [4] - Zhuhai Guanyu has won a final ruling from the Supreme People's Court, dismissing the lawsuit from ATL, with 14 ATL patents declared invalid and no negative impact on the company's operations [5] - Lixing Co. has terminated the acquisition of Qingdao Feiyan Precision Steel Ball Manufacturing Co. due to failure to reach an agreement, with no adverse effects on its financial status [6] Group 3 - Pinming Technology expects a net profit of 28 million to 34 million yuan for the first half of the year, representing a year-on-year increase of 231.79% to 302.89% [7] - Tiande Yu's performance report anticipates a net profit of 152 million yuan for the first half, up 50.89% year-on-year [7] - Huahong Technology reports normal operations with no undisclosed significant matters [8]

Core Viewpoint - Toxin Pharmaceutical (301089.SZ) announced an investment of 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, aiming to leverage its technological advantages in the field of chemical and synthetic biology [1] Group 1: Investment Details - The investment consists of 223,400 yuan added to registered capital, with the remainder allocated to capital reserves [1] - Following the investment, Toxin Pharmaceutical will hold a direct stake of 1.75% in Jinsan Biotechnology [1] Group 2: Company Overview - Jinsan Biotechnology specializes in the research, production, and sales of synthetic biological products, focusing on the development and industrial application of ergothioneine [1] - The company has achieved breakthroughs in the entire chain of technology, including strain construction, fermentation, purification, and engineering-scale production of high-purity ergothioneine [1] Group 3: Market Potential - The market for ergothioneine terminal products in China is projected to reach 1.57 billion yuan by 2024, with 60% used in skincare and nearly 30% in health food [3] - The global ergothioneine raw material market is expected to grow from 6.3 million USD in 2024 to 16.1 million USD by 2031, with a CAGR exceeding 14% [3] Group 4: Controversies - Ergothioneine has faced controversies, including claims by a prominent biologist labeling it as a "fake drug," which has been disputed by related companies citing scientific backing [4]